PHP
PTLA

Parkman Healthcare Partners’s Portola Pharmaceuticals, Inc. PTLA Stock Holding History

Parkman Healthcare Partners’s Portfolio PTLA Stock Details PTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-275,505
Closed -$6.58M – 82
2019
Q4 		$6.58M Buy
+275,505
New +$7.6M 1.9% 22

Other funds holding PTLA

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $33.3B AUM 44.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
JSP
Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
CCM
Cadian Capital Management New York $821M AUM 14.36% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Fiera Capital (Canada)
Fiera Capital (Canada) Montreal, Quebec, Canada $27.6B AUM 23.56% 1-Year Est. Return

Parkman Healthcare Partners's PTLA Position: Q1 2020 in Review

Parkman Healthcare Partners sold out of Portola Pharmaceuticals, Inc. (PTLA) in Q1 2020, closing a stake of 275,505 shares — an estimated $6.58M sold.

Parkman Healthcare Partners first reported a position in PTLA in Q4 2019 and held it in 1 quarter. The position peaked at $6.58M in Q4 2019. 187 funds tracked by Wall St. Rank hold PTLA as of Q1 2020.

  • Parkman Healthcare Partners reported no remaining Portola Pharmaceuticals, Inc. position as of Q1 2020 after selling out during the quarter.
  • Parkman Healthcare Partners sold 275,505 Portola Pharmaceuticals, Inc. shares in Q1 2020, an estimated $6.58M.
  • Parkman Healthcare Partners first reported a position in Portola Pharmaceuticals, Inc. in Q4 2019 and held it in 1 quarter.
  • Parkman Healthcare Partners's Portola Pharmaceuticals, Inc. position peaked at $6.58M in Q4 2019.
  • 187 funds tracked by Wall St. Rank held Portola Pharmaceuticals, Inc. as of Q1 2020.

Based on Parkman Healthcare Partners's 13F filing for Q1 2020, filed 15 May 2020.